DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Max Healthcare Institute Limited — Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B)

NSE 52 min ago·29 Oct 2026, 3:58 pm

MAX Healthcare INS

Max Healthcare Institute has informed stock exchanges that it is currently facing pending litigation or disputes. This disclosure relates to a specific sub-paragraph under Para B of its filings, indicating that the company is involved in legal proceedings that have not yet been concluded.

For investors, this news highlights a potential risk factor that could impact the company's financial health or reputation. While the details of the specific dispute are not immediately clear, any unresolved legal issues can sometimes lead to unexpected financial liabilities or operational distractions.

Investors should monitor the exchange filings for further updates. It is important to wait for the company to provide more clarity on the nature and potential impact of these disputes before drawing any conclusions about the stock's future performance.